Diamel Therapy in Polycystic Ovary Syndrome Reduces Hyperinsulinaemia, Insulin Resistance, and Hyperandrogenaemia

Table 6

Evolution of the insulin sensitivity index (Raynaud) in patients with the polycystic ovary syndrome.

	n	Diamel	n	Placebo
Raynaud start	18	0.27±0.1 ***	19	0.24±0.1 ***
Raynaud 3 months	17	0.52±0.3 *	16	0.40±0.2 *
Raynaud 6 months	16	0.54±0.3 **	16	0.43±0.24 **

* 𝑃=0.03.
** 𝑃=0.005.
Values are means ± SD.